Antibody-drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?

被引：2

作者：

Guidi, Lorenzo ^{[1
,2
]}

Valenza, Carmine ^{[1
,2
]}

Trapani, Dario ^{[1
,2
]}

Curigliano, Giuseppe ^{[1
,2
]}

机构：

[1] IRCCS, European Inst Oncol, Div New Drugs & Early Drug Dev Innovat Therapies, Via Ripamonti 435, I-20141 Milan, Italy

[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2023年 / 23卷 / 11期

关键词：

Agnosticisms; HER2; HER2-amplified solid tumors; HER2-mutant solid tumors; TRASTUZUMAB EMTANSINE; OPEN-LABEL; CANCER;

D O I：

10.1080/14712598.2023.2277915

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：1039 / 1042

页数：4

共 25 条

[1] Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, 3 trial [J].

Andre, Fabrice ;

Park, Yeon Hee ;

Kim, Sung-Bae ;

Takano, Toshimi ;

Im, Seock-Ah ;

Borges, Giuliano ;

Lima, Joao Paulo ;

Aksoy, Sercan ;

Gavila Gregori, Joaquin ;

De Laurentiis, Michelino ;

Bianchini, Giampaolo ;

Roylance, Rebecca ;

Miyoshi, Yasuo ;

Armstrong, Anne ;

Sinha, Rajni ;

Ruiz Borrego, Manuel ;

Lim, Elgene ;

Ettl, Johannes ;

Yerushalmi, Rinat ;

Zagouri, Flora ;

Duhoux, Francois P. ;

Fehm, Tanja ;

Gambhire, Dhiraj ;

Cathcart, Jillian ;

Wu, Cai ;

Chu, Changan ;

Egorov, Anton ;

Krop, Ian .

LANCET, 2023, 401 (10390) :1773-1785

[2] Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review [J].

Blange, Dionne ;

Stroes, Charlotte I. ;

Derks, Sarah ;

Bijlsma, Maarten F. ;

van Laarhoven, Hanneke W. M. .

CANCER TREATMENT REVIEWS, 2022, 108

[3] Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? [J].

Corti, Chiara ;

Antonarelli, Gabriele ;

Valenza, Carmine ;

Nicolo, Eleonora ;

Rugo, Hope ;

Cortes, Javier ;

Harbeck, Nadia ;

Carey, Lisa A. ;

Criscitiello, Carmen ;

Curigliano, Giuseppe .

EUROPEAN JOURNAL OF CANCER, 2022, 171 :25-42

[4]

Gion Maria, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_351222

[5] A Note From History: Landmarks in History of Cancer, Part 6 [J].

Hajdu, Steven I. ;

Vadmal, Manjunath .

CANCER, 2013, 119 (23) :4058-4082

[6] Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial [J].

Hecht, J. Randolph ;

Bang, Yung-Jue ;

Qin, Shukui K. ;

Chung, Hyun C. ;

Xu, Jianming M. ;

Park, Joon O. ;

Jeziorski, Krzysztof ;

Shparyk, Yaroslav ;

Hoff, Paulo M. ;

Sobrero, Alberto ;

Salman, Pamela ;

Li, Jin ;

Protsenko, Svetlana A. ;

Wainberg, Zev A. ;

Buyse, Marc ;

Afenjar, Karen ;

Houe, Vincent ;

Garcia, Agathe ;

Kaneko, Tomomi ;

Huang, Yingjie ;

Khan-Wasti, Saba ;

Santillana, Sergio ;

Press, Michael F. ;

Slamon, Dennis .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (05) :443-+

[7] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial [J].

Hurvitz, Sara A. ;

Hegg, Roberto ;

Chung, Wei-Pang ;

Im, Seock-Ah ;

Jacot, William ;

Ganju, Vinod ;

Chiu, Joanne Wing Yan ;

Xu, Binghe ;

Hamilton, Erika ;

Madhusudan, Srinivasan ;

Iwata, Hiroji ;

Altintas, Sevilay ;

Henning, Jan-Willem ;

Curigliano, Giuseppe ;

Perez-Garcia, Jose Manuel ;

Kim, Sung-Bae ;

Petry, Vanessa ;

Huang, Chiun-Sheng ;

Li, Wei ;

Frenel, Jean-Sebastien ;

Antolin, Silvia ;

Yeo, Winnie ;

Bianchini, Giampaolo ;

Loi, Sherene ;

Tsurutani, Junji ;

Egorov, Anton ;

Liu, Yali ;

Cathcart, Jillian ;

Ashfaque, Shahid ;

Cortes, Javier .

LANCET, 2023, 401 (10371) :105-117

[8] THE BIOLOGY OF ERBB-2 NEU HER-2 AND ITS ROLE IN CANCER [J].

HYNES, NE ;

STERN, DF .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1994, 1198 (2-3) :165-184

[9] Neratinib plus fulvestrant plus trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial [J].

Jhaveri, K. ;

Eli, L. D. ;

Wildiers, H. ;

Hurvitz, S. A. ;

Guerrero-Zotano, A. ;

Unni, N. ;

Brufsky, A. ;

Park, H. ;

Waisman, J. ;

Yang, E. S. ;

Spanggaard, I. ;

Reid, S. ;

Burkard, M. E. ;

Vinayak, S. ;

Prat, A. ;

Arnedos, M. ;

Bidard, F. -C. ;

Loi, S. ;

Crown, J. ;

Bhave, M. ;

Piha-Paul, S. A. ;

Suga, J. M. ;

Chia, S. ;

Saura, C. ;

Garcia-Saenz, J. a. ;

Gambardella, V. ;

de Miguel, M. J. ;

Gal-Yam, E. N. ;

Raphael, A. ;

Stemmer, S. M. ;

Ma, C. ;

Hanker, A. B. ;

Ye, D. ;

Goldman, J. W. ;

Bose, R. ;

Peterson, L. ;

Bell, J. S. K. ;

Frazier, A. ;

Diprimeo, D. ;

Wong, A. ;

Arteaga, C. L. ;

Solit, D. B. .

ANNALS OF ONCOLOGY, 2023, 34 (10) :885-898

[10] Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer [J].

Li, Bob T. ;

Smit, Egbert F. ;

Goto, Yasushi ;

Nakagawa, Kazuhiko ;

Udagawa, Hibiki ;

Mazieres, Julien ;

Nagasaka, Misako ;

Bazhenova, Lyudmila ;

Saltos, Andreas N. ;

Felip, Enriqueta ;

Pacheco, Jose M. ;

Perol, Maurice ;

Paz-Ares, Luis ;

Saxena, Kapil ;

Shiga, Ryota ;

Cheng, Yingkai ;

Acharyya, Suddhasatta ;

Vitazka, Patrik ;

Shahidi, Javad ;

Planchard, David ;

Janne, Pasi A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (03) :241-251

← 1 2 3 →